Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04540900 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions
A Phase 1 study of Wrinkle and Fine Lines, sponsored by Krystal Biotech.
- Active
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
- 4
- Study locations
NCT04540900: Active Phase 1 study of Wrinkle and Fine Lines, sponsored by Krystal Biotech.
NCT04540900 is a Phase 1 study of Wrinkle and Fine Lines that is active but no longer recruiting, run by Krystal Biotech. The registered enrollment target is 85 participants, below the 117-participant average among 25 other Wrinkle trials with a reported enrollment target (27% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04540900, a Phase 1 study of Wrinkle and Fine Lines, is active but no longer recruiting, sponsored by Krystal Biotech.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
- 4
- Study locations
Study Summary
A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions
Primary Outcome
The primary outcome will look at the safety and tolerability of KB301 through the collection and quantification of adverse events, physical examinations, vital signs and clinical laboratory tests.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL KB301
Study Locations (4)
California
- Aesthetx - Campbell
- Steve Yoelin, MD Medical Associates, Inc. - Newport Beach
- Mission Dermatology - Rancho Santa Margarita
Florida
- Skin and Cancer Associates, LLP. D/B/A Center for Clinical and Cosmetic Research - Aventura
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2020-10-07 |
| Est. Completion | 2029-05-31 |
| Phase | Phase 1 |
What the registry record for NCT04540900 still lists
NCT04540900 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 117-participant average among 25 other Wrinkle trials with a reported enrollment target (27% lower).
The record links to 4 conditions, with Wrinkle appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04540900 reports a single indexed study location in California, Florida.
Frequently Asked Questions
What is clinical trial NCT04540900 about?
NCT04540900 is a clinical study titled "A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions". A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions
What is the current status of trial NCT04540900?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2020-10-07. Estimated completion is 2029-05-31.
What conditions does trial NCT04540900 study?
This clinical trial studies the following conditions: Wrinkle, Fine Lines, Skin Roughness, Skin Thickness.
What interventions are being tested in trial NCT04540900?
The interventions under investigation include: Placebo (OTHER), KB301 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04540900?
This trial is sponsored by Krystal Biotech, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04540900 being conducted?
This trial has 4 study locations across California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wrinkle
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04540900's enrollment target sits among peer trials
85 10th of 25 higher than 16 of 25 other Wrinkle trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Wrinkle trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effects of Topical Almond Oil and Tretinoin on Facial Wrinkles
RECRUITING · NA
-
AVAVA MIRIA General Use
RECRUITING · NA
-
Assessing the Impact of Botulinum Toxin Type A on Facial Wrinkles: A Comprehensive Clinical Investigation
RECRUITING
-
Feasibility Study to Collect and Assess Safety Data for a Radiofrequency Microneedling Device for Electrocoagulation and Hemostasis of Soft Tissues for Dermatologic Conditions
RECRUITING · NA
-
The Effects of Almond on Facial Skin Collagen and Wrinkles
RECRUITING · NA
-
A Prospective Controlled Study to Evaluate the Safety and Effectiveness of Thermage® FLX Radiofrequency Treatment
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI